Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 177 clinical trials
The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

Anti-melanoma differentiation-associated gene5 (Anti-MDA5) antibody positive Dermatomyositis (DM) is a subtype of DM that is more frequent in East Asia, which is often exhibit skin lesion

  • 0 views
  • 25 Jul, 2021
  • 1 location
Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis

The use of lipid lowering agents in patients with idiopathic inflammatory myopathies is controversial. Therefore, the aim of the present study is to assess clinically and laboratory the impact of lipid-lowering agents in this population.

polymyositis
  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of

dermatomyositis
prednisolone
rheumatism
a 10
rash
  • 13 views
  • 14 Jun, 2021
  • 103 locations
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

treatment with KZR-616 in patients with active Polymyositis (PM) or Dermatomyositis (DM). Patients will be evaluated for eligibility during the Screening Period. Eligible patients will be randomized 1:1 to

dermatomyositis
muscle enzyme
weakness
body mass index (bmi)
mdga
  • 85 views
  • 26 Jan, 2021
  • 29 locations
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.

lupus
mycophenolate
azathioprine
antimalarials
leflunomide
  • 198 views
  • 26 Jul, 2021
  • 223 locations
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

The main objective of this study is to evaluate the safety and efficacy of elsubrutinib, upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.

lupus
mycophenolate
rash
cyclosporine
antimalarials
  • 413 views
  • 28 Jul, 2021
  • 301 locations
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

lupus
  • 503 views
  • 25 Jul, 2021
  • 557 locations
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to 17 years of age with SLE on a background of standard of care therapy. This bridging …

hydroxychloroquine
mycophenolate
belimumab
cyclosporine
oral cyclophosphamide
  • 2 views
  • 26 Jan, 2021
  • 12 locations
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies.

lupus
mycophenolate
pericarditis
rheumatism
hydroxychloroquine
  • 44 views
  • 23 Jun, 2021
  • 231 locations
A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus

This is a first exploration of GLPG3970 in subjects with active systemic lupus erythematosus (SLE) to evaluate the effect on disease biomarkers and to determine its pharmacokinetics (PK) profile, safety and tolerability, and pharmacodynamics (PD) biomarkers related to the investigational product (IP) mechanism of action and the pathophysiology of SLE.

lupus
mycophenolate
hydroxychloroquine
chloroquine
nsaids
  • 0 views
  • 03 Jul, 2021
  • 12 locations